Detailansicht

Wissensnetz

Person

Kristian Reich

Arzt

Name	Kristian Reich
Ort	Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr. med.
Beruf	Arzt (charakteristischer Beruf)
Beziehung	Germanistik, Philosophie, Humanmedizin (Studienfach)
Datensatztyp	Person
GND-Nummer	113916019
Datensatz-ID	113916019
Beteiligt an alle anzeigen Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA) Brodalumab versus guselkumab in patients with moderate-to-severe psoriasis with an inadequate response to ustekinumab: a randomized, multicenter, double-blind phase 4 trial (COBRA) Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis : : the GUIDE randomized clinical trial Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE) A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE) COVID‐19 and implications for dermatological and allergological diseases COVID‐19 and implications for dermatological and allergological diseases Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : results from the CLEAR study Haut : gesund, schön, gepflegt Alitretinoin : Fälle aus der Praxis Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis : report on five cases German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version) Tumor necrosis factor polymorphisms in psoriatic arthritis : association with the promoter polymorphism TNF-857 independent of the PSORS1 risk allele Phänotypische und funktionelle Untersuchungen zu Veränderungen im intestinalen Immunsystem bei chronisch-entzündlichen Darmerkrankungen

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Kristian Reich

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)

Brodalumab versus guselkumab in patients with moderate-to-severe psoriasis with an inadequate response to ustekinumab: a randomized, multicenter, double-blind phase 4 trial (COBRA)

Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis : : the GUIDE randomized clinical trial

Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary

Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)

COVID‐19 and implications for dermatological and allergological diseases

COVID‐19 and implications for dermatological and allergological diseases

Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : results from the CLEAR study

Haut : gesund, schön, gepflegt

Alitretinoin : Fälle aus der Praxis

Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis : report on five cases

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)

Tumor necrosis factor polymorphisms in psoriatic arthritis : association with the promoter polymorphism TNF-857 independent of the PSORS1 risk allele

Phänotypische und funktionelle Untersuchungen zu Veränderungen im intestinalen Immunsystem bei chronisch-entzündlichen Darmerkrankungen